TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA<sub>A</sub> receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia.

Neuropsychopharmacology · 2018 · PMC6180114 · PMID 30093697

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A double-blind, placebo-controlled trial of MK-0777 in schizophrenia patients on stable doses of antipsychotic medications showed a trend for improvement in three working memory tasks [ 6 ].

also in 53,322 other papers

a strong trendno p-value reported

We also observed a strong trend of reversal of scPCP-induced LTP impairment in the scPCP mice given acute TPA-023 (unpublished).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.